Insecticides India Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 May 2026 | Fertilizers & Agrochemicals | Market Cap: ₹1.8K Cr
FY'26 growth expected to be good and positive, though not necessarily another jump (Rajesh Kumar Aggarwal). FY'26 growth is expected to be good with a bullish and positive outlook, though not necessarily experiencing a sharp jump (Rajesh Kumar Aggarwal, Page 16-17). - Focus on continuous premiumization and improving product mix, increasing focused Maharatna products from 12 to 16, indicating growth potential (Page 16). - Margin improvement expected slowly over 2-3 years with 200-300 basis points increase in EBITDA margins (Page 15-16). - The company targets double-digit growth consistently, aiming to beat the industry average (Page 9). - Kaeros subsidiary expected to profit around Rs.
From Insecticides India Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹610
Market Cap
₹1.8K Cr
P/E Ratio
14.7
How does Insecticides India Ltd rank in Fertilizers & Agrochemicals?
Compare Insecticides India Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Insecticides India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹385 Cr, net profit ₹10 Cr.
Full financials →📊 Revenue & Sales Performance
- →FY'26 growth expected to be good and positive, though not necessarily another jump (Rajesh Kumar Aggarwal).
- →Strategy focused on premiumization with continuous new product launches and improved product mix.
- →Target to increase Focused Maharatnas from 12 to 16, with support via advertising and development.
- →Launch of mega new products including collaborations and IP-protected mixtures planned.
- →Anticipated double-digit volume growth with value growth reflecting volume plus modest price improvements.
- →Long-term outlook includes continuous EBITDA margin improvements by 200-300 bps over 2-3 years.
- →Export contribution currently 5%, expected to grow gradually without dramatic shifts.
- →Working capital and inventory buildup aimed to support strong seasonal demand, indicating readiness for early monsoon sowing.
- →Overall, company expects to beat industry growth rates with steady, sustainable expansion based on innovations and premium offerings.
📈 Profitability & Margins
- →FY'26 growth is expected to be good with a bullish and positive outlook, though not necessarily experiencing a sharp jump (Rajesh Kumar Aggarwal, Page 16-17).
- →Focus on continuous premiumization and improving product mix, increasing focused Maharatna products from 12 to 16, indicating growth potential (Page 16).
- →Margin improvement expected slowly over 2-3 years with 200-300 basis points increase in EBITDA margins (Page 15-16).
- →The company targets double-digit growth consistently, aiming to beat the industry average (Page 9).
- →Kaeros subsidiary expected to profit around Rs. 10-12 crore in FY'26, with potential multiplication in subsequent years (Page 9-12).
- →Strong launch pipeline with new products including IP-protected formulations and collaborations, supporting future growth (Page 16).
- →Efforts to further improve efficiencies and reduce costs, supporting operating margins (Page 15).
🏗️ Capital Expenditure Plans
- →Completed Rs. 150 crores CAPEX for Dahej plant, which will contribute roughly Rs. 100 crores this fiscal with expected >50% CAGR in next 3-4 years.
- →New plant at Sotanala, Rajasthan, with about Rs. 50 crores already spent and an additional Rs. 100 crores planned for FY'26; this will be fully automatic and boost production capacity.
- →Ongoing maintenance CAPEX across plants to support expansions and efficiency.
- →Investment in utilities improvements to control power, gas, and oil budgets, aiming to reduce expenses per kg in both segments.
- →CAPEX related to export markets is routine, mainly for data generation and lab facilities, including 3-4 NABL labs and a GLP in-house lab.
- →Focus on launching premium, IPR-protected products and new formulations supported by recent CAPEX.
- →Strategic inventory buildup in preparation for the monsoon season and aggressive product launches.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →The company indicates there have been signals of shortages in the market for products like rice and corn herbicides, implying strong demand.
- →They have been building up inventory strategically since March to meet the upcoming season demand, particularly for aggressive product launches.
- →Despite manpower shortages temporarily impacting production, they are prepared to place products in the market effectively.
- →Demand for herbicides is expected to be good in June and beyond, although tightness due to manpower constraints may slightly affect supply.
- →There is no explicit numeric mention of an order book or pending orders volume, but the company expresses readiness to fulfill market demand and maintain growth.
- →The overall outlook is positive with expectations to beat market growth and maintain double-digit top-line growth through sufficient inventory and strategic planning.
Key Metrics
Continue your research
What Insecticid.India's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Sharda Cropchem (Q4 FY25)
Globally, the company’s current 4%-5% global market share offers scope to increase, meaning a 1% global share gain equates to 20%-25% volume growth for them…
- Rallis India (Q4 FY25)
Export business has seen some recovery with a 6% growth in volume and price in Q4, suggesting improving order flow. Key concall takeaways from Rallis India's…
- Punjab Chemicals (Q4 FY25)
The company has created inventory strategically to honor its existing order book positions, with about INR25 crores of inventory lying in transit as of March…
- Gujarat State Fertilizers & Chemicals Ltd (Q4 FY25)
FY '25 manufacturing volumes were 1.6 million tons, a 15% YoY growth. Key concall takeaways from Gujarat State Fertilizers & Chemicals Ltd's Q4 FY25 earnings…
Frequently Asked Questions
What were Insecticides India Ltd Q4 FY25 results?
FY'26 growth expected to be good and positive, though not necessarily another jump (Rajesh Kumar Aggarwal). FY'26 growth is expected to be good with a bullish and positive outlook, though not necessarily experiencing a sharp jump (Rajesh Kumar Aggarwal, Page 16-17). - Focus on continuous premiumization and improving product mix, increasing focused Maharatna products from 12 to 16, indicating growth potential (Page 16). - Margin improvement expected slowly over 2-3 years with 200-300 basis points increase in EBITDA margins (Page 15-16). - The company targets double-digit growth consistently, aiming to beat the industry average (Page 9). - Kaeros subsidiary expected to profit around Rs.
What is Insecticides India Ltd share price analysis?
Insecticides India Ltd currently shows a neutral. The stock trades at a P/E of 14.7 with a market cap of ₹1,837 Cr. Investors should review the full earnings analysis for detailed insights.
Is Insecticides India Ltd planning capital expenditure?
Completed Rs.
Keep Insecticides India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.